Document is current

Any future updates will be listed below

Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA

Crossref DOI link: https://doi.org/10.1007/s12325-022-02273-4

Published Online: 2022-08-09

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark